The American Journal of Surgery
Volume 199, Issue 1, Supplement , Pages S11-S20, January 2010

Prevention and management of venous thromboembolism in the surgical patient: options by surgery type and individual patient risk factors

  • James E. Muntz, M.D.

      Affiliations

    • Baylor College of Medicine, Houston, TX, USA
    • Memorial Hermann Sports Medicine Institute, University of Texas Health Center, Houston, TX, USA
    • Corresponding Author InformationCorresponding author. Tel.: 1+713-795-4847; fax: 1+713-795-0774
  • ,
  • Franklin A. Michota, M.D.

      Affiliations

    • Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, USA
    • Department of Hospital Medicine, Cleveland Clinic, Cleveland, OH, USA

Received 23 July 2009; received in revised form 27 October 2009

Abstract 

Background

Current evidence-based guidelines provide recommendations for prophylaxis and treatment of venous thromboembolism (VTE) in a variety of surgical patients.

Data sources

A systematic Ovid Medline search (from 1950 to the present) was conducted for relevant articles using the following search terms: “venous thromboembolism,” “thrombophlebitis,” “thromboembolism,” “pulmonary embolism,” “heparin,” “low-molecular-weight heparin,” “postoperative complications,” and “anticoagulants.”

Conclusions

Pharmacologic and mechanical approaches are available for VTE prophylaxis, including low-dose unfractionated heparin, low-molecular-weight heparin, vitamin K antagonists, fondaparinux, intermittent pneumatic compression devices, and graduated compression stockings. Permanent inferior vena cava filters are not recommended for primary VTE prophylaxis, although they do have a role in the prevention of pulmonary embolism in patients with recent VTE who cannot have surgery delayed. Retrievable inferior vena cava filters are under investigation for primary VTE prophylaxis in trauma patients. New anticoagulants that inhibit factor Xa and thrombin will soon be available for the prevention and treatment of VTE in surgical patients.

Keywords: Deep vein thrombosis, Venous thromboembolism, Pulmonary embolism, Prophylaxis, Treatment, Guidelines

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Dr Muntz is a member of the advisory boards of Boehringer Ingelheim, Johnson & Johnson, and sanofi-aventis; a consultant for Bayer AG, Boehringer Ingelheim GmbH, sanofi-aventis, and Johnson & Johnson; and a member of the speakers' bureau of sanofi-aventis. Dr Michota is a member of the advisory boards of sanofi-aventis, Osaka Pharmaceuticals, Genentech Inc, and Ortho-McNeil/Johnson & Johnson and is a consultant and a member of the speakers' bureau of sanofi-aventis, Osaka Pharmaceuticals, and Genentech Inc.

PII: S0002-9610(09)00646-1

doi:10.1016/j.amjsurg.2009.10.007

The American Journal of Surgery
Volume 199, Issue 1, Supplement , Pages S11-S20, January 2010